• Mass spectrometry research aims for 1,000-fold improvement in pharma imaging technology
    Imaging technology used by pharma firms could be more sensitive following research based on mass spectrometry

Bioanalytical

Mass spectrometry research aims for 1,000-fold improvement in pharma imaging technology

Jul 14 2010

Research being conducted at Case Western Reserve University aims for a 1,000-fold enhancement of the mass spectrometry-based structural imaging technology used by pharma developers.

Dr Mark Chance, director of the university's school of medicine's Centre for Proteomics and Bioinformatics, explains that examining the structure of G-protein coupled receptors and similar membrane proteins is difficult.

However, pharma developers must determine how drugs are able to switch on and off those receptors if they are able to create therapeutics for diabetes, heart failure and depression.

Using mass spectrometry techniques, Dr Chance and his team succeeded in capturing a high-resolution image of the open state of a potassium channel, enabling analysis of gating mechanisms with applications in nerve signalling and heart function.

The 1,000-fold enhancement in imaging is one of the primary aims of the group led by Dr Chance, whose research focuses on the potential of structural genomics initiatives made possible by high-throughput analysis.

Digital Edition

Chromatography Today - Buyers' Guide 2022

October 2023

In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions

Events

Korea Lab 2024

Apr 23 2024 Kintex, South Korea

Korea Chem 2024

Apr 23 2024 Seoul, South Korea

AOCS Annual Meeting & Expo

Apr 28 2024 Montreal, Quebec, Canada

SETAC Europe

May 05 2024 Seville, Spain

ChemUK 2024

May 15 2024 Birmingham, UK

View all events